Imagion Biosystems has lodged Pro-Rata Non-Renounceable Rights Issue: Notice under section 708AA(2)(f) of the Corporations Act 2001 (Cth) with the Australian Securities Exchange.
View the Pro-Rata non-Renounceable Rights Issue announcement.
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
June 3, 2026
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)